TP53RK in Multiple Myeloma: A New Therapeutic Target?

Share this content:
p53-related protein kinase (TP53RK) is a targetable prognostic marker for patients with multiple myeloma.
p53-related protein kinase (TP53RK) is a targetable prognostic marker for patients with multiple myeloma.

p53-related protein kinase (TP53RK) is a targetable prognostic marker for patients with multiple myeloma, according to an article published in Blood.1

A profile of genetic expression suggested that increased TP53RK expression is a causal factor of normal plasma cells progressing into myeloma cells. For this paper, the authors analyzed the gene expression profiles of myeloma cells to determine the role of TP53RK in myeloma progression, and whether TP53RK inhibition is likely to improve clinical outcomes.

Cells from patients with active disease had high TP53RK expression, suggesting that TP53RK levels predict disease progression. Patients with newly-diagnosed disease had shorter survival if tumor cells had high TP53RK expression.

Immunomodulatory agents such as pomalidomide were shown to bind to TP53RK and “inhibit its kinase activity.” This inhibition triggered myeloma cell apoptosis, though it is unclear whether this method would be effective in clinical settings.

RELATED: MGUS: Determining Significance in Multiple Myeloma

The authors concluded that TP53RK expression is both a prognostic marker and a therapeutic target for patients with multiple myeloma. More research is needed, however, to develop selective TP53RK inhibitors.

Reference

  1. Hideshima T, Cottini F, Nozawa Y, et al. p53-related protein kinase confers poor prognosis and represents a novel therapeutic target in multiple myeloma. Blood. 2017 Jan 12. 10.1182/blood-2016-09-738500 [Epub ahead of print

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters